Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus mFOLFOX6 after surgery for colorectal cancer
ChiCTR1800019212Phase 4Not yet recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Nov 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib, oxaliplatin, fluorouracil and folinic acid in colorectal cancer (CRC), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoint: Disease-free survival. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
Rivoceraniboxaliplatinfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR1800019212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019212.